Metadata

Dataset ID: 22
Back to List

Study Design
Study Design Background Sudy of rare disease (aceruplasmonemia) using Cp KO mouse model to highlight gender differences in disease behaviour in view of a possible replacement therapy. Labeling of Ceruloplasmine (Cp) with Cu-64 to follow its in vivo distribution in the model. Study of inflammation.
Study Description Ceruloplasmin administration in the preclinical mouse model of aceruloplasminemia reveals a sex-related variation in biodistribution
Study Type preclinical
Study Subtype in vivo and post mortem
Publication
Paper Linked yes
Paper Title Ceruloplasmin administration in the preclinical mouse model of aceruloplasminemia reveals a sex-related variation in biodistribution
Paper Authors Sara Belloli, Cristina Monterisi, Paolo Rainone, AngelaColiva, Alan Zanardi, Antonio Conti, Andrea Caricasole, Rosa Maria Moresco & Massimo Alessio
Affiliation 1. Nuclear Medicine and PET Cyclotron Unit, IRCCS-Ospedale San Raffaele, Milano, Italy. 2. Institute of Bioimaging and Complex Biological Systems, CNR, Segrate, MI, Italy. 3. Medicine and Surgery Department, University of Milano - Bicocca, Monza, MB, Italy. 4. Proteome Biochemistry, COSR-Center for Omics Sciences, IRCCS-Ospedale San Raffaele, Milano, Italy. 5. Research and Innovation, Kedrion S.p.A., Loc. Bolognana, Gallicano, LU, Italy. 6. Proteome Biochemistry, COSR-Center for Omics Sciences, IRCCS-Ospedale San Raffaele, Milano, Italy.
Paper Journal Communications biology
Paper Year 2025
Paper Doi https://doi.org/10.1038/s42003-025-07714-8
Open Access yes
Study Component
Multi Modality Images no
Imaging Modality PET/CT
Radiation yes
Imaging Coverage whole body
Imaging Target Copper transporter, TSPO receptor
Dataset Information
Institution IBSBC-CNR
Pi Massimo Alessio
Co Pi Rosa Maria Moresco
Country Of Institution Italy
Imaging Facility Laboratory of Preclinical Molecular Imaging
Euro Bio Imaging Node Multi-Modal Molecular Imaging Italian node (MMMI)
Country Of Imaging Facility Italy
Funding yes
Funding Agency Ricerca Finalizzata 2018, Italian Ministry ofHealth (RF-2018-12366471), Eu-BI MMMI FOE 2021, PNRR See Life Project IR0000023
Dataset Access public
License CC BY-NC-ND 4.0
Duo Data Use Permission DUO:0000042
Duo Data Use Modifier DUO:0000020
Duo Investigation DUO:0000032
Contact Person sara.belloli@cnr.it; alessio.massimo@hsr.it
In Vivo Experimental Parameters
Number Of Groups 8
Types Of Groups female adult wt, female wt aged, female adult KO, female aged KO, male adult wt, male wt aged, male adult KO, male aged KO
Overall Sample Size 48
Disease Model rare disease with neurological signs and inflammation
Organ Or Tissue brain and liver
Sample Size For Each Group 6 per each group
Power Calculation G*Power
Randomization no
Blinding no
Species Mice
Strain C57BL/6
Immune Status immunocompetent
Sex female and male
Age adult and aged
Age At Start Experiment 6 months
Weight 40 g
Genotype homozygous
Genetic Manipulation Cp KO
Gene Ceruloplasmine
Experimental Procedures
Pharmacological Procedures Intervention And Control no
Blood Sampling yes
Blood Sampling Method cardiac puncture before sacrifice
Blood Sample Volume 500 microliter
Blood Timing one
Surgical Procedures Including Sham Surgery no
Target Organ Tissue brain, eyes, liver, small intestine, lung, kidney, heart and chest muscle
Pathogen Infection Intervention And Control no
Analgesic Plan To Relieve Pain Suffering And Distress no
Anesthesia For Imaging yes
Anesthesia Type gas
Duration 30 minutes
Anesthesia Drugs isoflurane
Euthanasia yes
Method cardiac puncture and cervical dislocation
Histology yes
Tissues Collected Post Euthanasia brain, eyes, liver, small intestine, lung, kidney, heart and chest muscle
Timing Of Collection end of imaging
Imaging yes
Frequency Of Imaging one per group
Timing Of Imaging selected age of the Cp KO animals
Overall Scan Length 30 minutes
Contrast Agent Or Radio Isotope Or Challenge With Gas Molecule yes
Contrast Agent Commercial Drug [64Cu]-Ceruloplasmine; [18F]-VC701
Contrast Agent Chemical Drug [64Cu]-Ceruloplasmine; [18F]-3-Fluoromethyl-N-methyl-4-phenyl-N-(phenylmethyl) quinoline-2-carboxamide
Contrast Agent Dose 5.12 ± 0.25 MBq; 1.91 ± 0.27MBq
Injection Volume 50ul
Route Of Administration intravenous
Cell Lines no
Image Acquisition
Instrument Vendor Molecubes
Instrument Type β-cube, X-cube
Instrument Specifics PET: FOV of 72x130 mm; CT: FOV of 64x40 mm
Image Acquisition Parameters PET: 511 KeV, 30% energy resolution; CT: 40 kVp, 400 μA (0.8 mm Al filtration)
Correction PET: isotope decay and random coincidences correction; CT: ring artifact correction
Raw Data yes
Qa Qc yes
Image Correlation
Image Type Reconstructed and quantified images
Image Scale KBq/cc for PET and HU for CT
Format Compression raw, DICOM and NIFTI
Dimensions 2D/3D
Overall Number Of Images 1 dataset per animal per imaging technique per time point
Field Of View Max FOV for PET and CT
Dimension Extents PET/CT: 192x192x384
Size Description PET/CT: 76.8 x 76.8 x 154 mm
Pixel Voxel Size Description PET/CT: 400 µm isometric
Image Processing Methods CT-based normalization
Image Reconstruction Algorithm PET: OSEM (30 iterations); CT: ISRA (iterative)
Quality Control no
Analyzed Data
Data Used For Analysis SUVmean
Back to List